Labour peer says he opposes Corbyn-style state-funded drugs firm

12 November 2019 - A Labour peer has spoken out against the idea of a nationalised drugs industry, saying that ...

Read more →

The FDA needs to set standards for using artificial intelligence in drug development

7 November 2019 - Artificial intelligence has become a crucial part of our technological infrastructure and the brain underlying many ...

Read more →

Wanted: better policies and incentives to revitalise R&D for new antimicrobial drugs

15 October 2019 - In the not-too-distant future that we could be facing — one with rampant, uncontrollable, multidrug-resistant microbes ...

Read more →

FDA cuts red tape in diagnosis applications for cancer trials

10 October 2019 - Drug companies developing cancer treatments can fold the risk assessment of unapproved screening tests into their ...

Read more →

FDA awards 12 grants to fund new clinical trials to advance the development of medical products for the treatment of rare diseases

8 October 2019 - The U.S. FDA today announced that it has awarded 12 new clinical trial research grants totaling ...

Read more →

The real impact of drug price legislation on biopharmaceutical R&D

2 October 2019 - As outcry around drug prices rages, arguments continue to surface that limiting corporate revenues via price controls ...

Read more →

Novartis and Microsoft announce collaboration to transform medicine with artificial intelligence

1 October 2019 - Multi-year alliance underpins the Novartis commitment to leverage data & artificial intelligence to transform how medicines are ...

Read more →

AI needs patients’ voices in order to revolutionise health care

30 September 2019 - Patients’ stories — what doctors call patient histories — are the bedrock of medicine. “Listen to ...

Read more →

FDA issues draft guidance on patient-focused drug development: methods to identify what is important to patients

30 September 2019 - Today the U.S. FDA issued a draft guidance on Patient-Focused Drug Development: Methods to Identify What Is ...

Read more →

Interacting with the FDA on complex innovative trial designs for drugs and biological products

20 September 2019 - This document provides guidance to sponsors and applicants on interacting with the FDA on complex innovative trial ...

Read more →

FDA seeks input on product-specific guidances to facilitate generic drug development

16 September 2019 - Today, FDA published 53 product-specific guidances (PSGs) – 34 new guidances and 19 revised guidances, including ...

Read more →

Subscription model for antibiotic development

6 September 2019 - An unlikely answer to the global crisis in antibiotic resistance. ...

Read more →

Who’s missing from breast cancer trials? Men, says the FDA

9 September 2019 - Men do get breast cancer, but they account for fewer than 1 percent of patients and often ...

Read more →

Promoting paediatric drug research and labelling — outcomes of legislation

28 August 2019 - Congress has modified regulations of the FDA to promote research assessing the efficacy and safety of drugs ...

Read more →

FDA urges inclusion of men in breast cancer clinical trials

28 August 2019 - Men with breast cancer make up less than one percent of all breast cancer cases, but ...

Read more →